|Day Low/High||1.01 / 1.06|
|52 Wk Low/High||1.16 / 2.75|
Abstract Selected for Podium Presentation and Inclusion in 2017 AUA Press Conference
Female Health Co./Veru Healthcare's stock is down, but the company says it's not out.
Stage 1 of Clinical Trial Designed to Select Formulation; NDA Filing Under the 505(b)(2) Regulatory Pathway Late 2017 / Early 2018 And Approval Expected by Mid to Late 2018
-MSS-722 to Advance into Phase 2 Study; Trial Expected to Commence in 2017-
Company Plans to Launch Product in US Before Year End
Company Promotes Denise van Dijk to President of Global Public Health Sector Division
Company to Discuss Clinical Trial Design and Primary Clinical Endpoints for Phase 2 Study of Its Drug Candidate for Male Infertility
Remaining Proposals Close to Receiving the Required Super Majority Vote
Although many biotechnology stocks have fallen this year due to disappointing clinical trial results, what is the deal with this stock that is down precipitously despite encouraging R&D news?
ISS Changes Recommendation to Favorable
Three Proposals Have Received Required Majority Vote, Three Other Proposals Close to Receiving Required Super Majority Vote